Harvard Bioscience (NASDAQ:HBIO) and PerkinElmer (NYSE:PKI) are both computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

73.4% of Harvard Bioscience shares are held by institutional investors. Comparatively, 95.8% of PerkinElmer shares are held by institutional investors. 7.6% of Harvard Bioscience shares are held by company insiders. Comparatively, 2.1% of PerkinElmer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Harvard Bioscience has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, PerkinElmer has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

Dividends

PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. Harvard Bioscience does not pay a dividend. PerkinElmer pays out 9.7% of its earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Harvard Bioscience and PerkinElmer, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience 0 0 2 0 3.00
PerkinElmer 0 8 4 0 2.33

Harvard Bioscience currently has a consensus target price of $9.50, indicating a potential upside of 88.12%. PerkinElmer has a consensus target price of $82.31, indicating a potential downside of 14.50%. Given Harvard Bioscience’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Harvard Bioscience is more favorable than PerkinElmer.

Valuation & Earnings

This table compares Harvard Bioscience and PerkinElmer’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $101.88 million 1.81 -$860,000.00 $0.05 101.00
PerkinElmer $2.26 billion 4.72 $292.63 million $2.90 33.19

PerkinElmer has higher revenue and earnings than Harvard Bioscience. PerkinElmer is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Harvard Bioscience and PerkinElmer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harvard Bioscience -4.46% 4.64% 2.62%
PerkinElmer 5.51% 14.25% 6.29%

Summary

PerkinElmer beats Harvard Bioscience on 10 of the 16 factors compared between the two stocks.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

PerkinElmer Company Profile

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix and PerkinElmer. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.